Search
Sanofi SA
SNYAdd to Watchlist
44.820USD
-0.020-0.04%
Close 08-28 16:00（ET）
107.41BMarket Cap
12.46P/E TTM
More Details of Sanofi SA Company
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Sanofi SA Profile
Ticker SymbolSNY
Company nameSanofi SA
IPO dateJul 01, 2002
CEOHudson (Paul)
Number of employees84587
Security typeDepository Receipt
Fiscal year-endJul 01
Address46 Avenue de la Grande Armee
CityPARIS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code75017
Phone33153774000
Websitehttps://www.sanofi.com/
Ticker SymbolSNY
IPO dateJul 01, 2002
CEOHudson (Paul)
Company Executives of Sanofi SA
Name
Name/Position
Position
Shareholding
Change
Ms. Rachel Duan
Ms. Rachel Duan
Independent Director
Independent Director
--
--
Ms. Lise Kingo
Ms. Lise Kingo
Independent Director
Independent Director
--
--
Ms. Natalie Bickford
Ms. Natalie Bickford
Chief People Officer, Executive Vice President, Member of the Executive Committee
Chief People Officer, Executive Vice President, Member of the Executive Committee
--
--
Mr. Thomas Triomphe
Mr. Thomas Triomphe
Executive Vice President - Vaccines, Member of the Executive Committee
Executive Vice President - Vaccines, Member of the Executive Committee
--
--
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Mr. Wolfgang Laux
Mr. Wolfgang Laux
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Roy Papatheodorou
Mr. Roy Papatheodorou
Executive Vice President, General Counsel, Member of the Executive Committee
Executive Vice President, General Counsel, Member of the Executive Committee
--
--
Mr. Brendan O'Callaghan
Mr. Brendan O'Callaghan
Executive Vice President - Manufacturing & Supply, Member of the Executive Committee
Executive Vice President - Manufacturing & Supply, Member of the Executive Committee
--
--
Ms. Carole Ferrand
Ms. Carole Ferrand
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Rachel Duan
Ms. Rachel Duan
Independent Director
Independent Director
--
--
Ms. Lise Kingo
Ms. Lise Kingo
Independent Director
Independent Director
--
--
Ms. Natalie Bickford
Ms. Natalie Bickford
Chief People Officer, Executive Vice President, Member of the Executive Committee
Chief People Officer, Executive Vice President, Member of the Executive Committee
--
--
Mr. Thomas Triomphe
Mr. Thomas Triomphe
Executive Vice President - Vaccines, Member of the Executive Committee
Executive Vice President - Vaccines, Member of the Executive Committee
--
--
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Mr. Wolfgang Laux
Mr. Wolfgang Laux
Director, Employee Representative
Director, Employee Representative
--
--
FAQs
Who are the top five shareholders of Sanofi SA?
The top five shareholders of Sanofi SA are: Ms. Rachel Duan
How many institutions hold shares of Sanofi SA (SNY)?
As of 2026Q1, 1330 institutions hold shares of Sanofi SA, with a combined market value of approximately 225.52M, accounting for 9.34% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -36323619.00.